Table 3.

Medication Dispensing Outcomes in Study Arms in Second Follow-Up Year: Unadjusted Mean Change from Baseline and Adjusted Intervention Effect

	Mean Absolute Change from Baseline Proportion in Each Practice (95% CI)			Adjusted Intervention Effect: Absolute Change beyond That Observed in Control Practices (95% CI)*
Outcome	PLE	PCI	Control	PLE	PCI
Among persistent asthmatics†
≥1 controller dispensed	0.09 (0.01, 0.17)	0.04 (−0.02, 0.1)	0.04 (−0.04, 0.12)	0.01 (−0.07, 0.08)	−0.03 (−0.09, 0.02)
≥3 controllers dispensed	0.07 (−0.01, 0.15)	0.11 (0.05, 0.17)	0.01 (−0.09, 0.11)	0.02 (−0.06, 0.10)	0.03 (−0.04, 0.10)
≥1 inhaled corticosteroid	0.19 (0.09, 0.29)	0.17 (0.08, 0.26)	0.12 (−0.01, 0.25)	0.02 (−0.11, 0.16)	−0.02 (−0.13, 0.09)
≥3 inhaled corticosteroid	0.14 (0.06, 0.22)	0.13 (0.08, 0.18)	0.04 (−0.07, 0.15)	0.07 (−0.02, 0.15)	0.03 (−0.04, 0.10)
Among all patients with asthma
≥1 controller dispensed	0.16 (0.08, 0.24)	0.13 (0.07, 0.19)	0.07 (−0.01, 0.15)	0.03 (−0.08, 0.15)	0.04 (−0.06, 0.14)
≥3 controllers dispensed	0.08 (0.02, 0.14)	0.10 (0.06, 0.14)	0.04 (−0.02, 0.10)	0.02 (−0.05, 0.09)	0.04 (−0.02, 0.09)
≥1 inhaled corticosteroid	0.18 (0.1, 0.26)	0.17 (0.11, 0.23)	0.10 (0.00,0.20)	0.05 (−0.08, 0.17)	0.04 (−0.06, 0.14)
≥3 inhaled corticosteroid	0.09 (0.03, 0.15)	0.09 (0.07, 0.11)	0.03 (−0.03, 0.09)	0.04 (−0.02, 0.10)	0.03 (−0.02, 0.07)
≥1 oral steroid dispensed‡	0.05 (0.00, 0.10)	0.04 (0.00, 0.08)	0.02 (−0.01, 0.05)	0.06 (0.00, 0.12)	0.07 (−0.02, 0.15)

^*Additional change in absolute proportion of children beyond that seen in control practices by patient-level analysis using generalized estimating equations accounting for clustering of observations within practice.

^†Persistent asthma defined using HEDIS criteria.

^‡Among all asthma patients, except for those receiving chronic oral steroids.

PLE, peer leader education; HEDIS, Health Plan Employer Data and Information Set; CI, confidence interval.